FilingReader Intelligence
Xinhua Pharmaceutical subsidiary gets finasteride drug certificate
August 5, 2025 at 09:10 AM UTC•By FilingReader AI
Shandong Xinhua Pharmaceutical's subsidiary received a drug registration certificate for finasteride tablets from China's National Medical Products Administration. The prescription drug treats benign prostatic hyperplasia and is covered by national medical insurance.
Public medical institutions in China recorded finasteride tablet sales of approximately 1.45 billion yuan in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000756•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Shandong Xinhua Pharmaceutical publishes news
Free account required • Unsubscribe anytime